{"filing":{"accession_number":"0001104659-26-082850","cik":"0000921114","ticker":"ARMP","company_name":"Armata Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"tm2620286d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/tm2620286d1_8k.htm"},"events":[{"id":17467,"run_id":15643,"accession_number":"0001104659-26-082850","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Armata announced FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, which the company characterizes as \"an important regulatory milestone\" on the path toward a future BLA. This is a material operational/regulatory milestone in the drug development process—it establishes the agreed framework for pediatric studies and is a prerequisite for BLA submission. While not a specific named event type (not earnings, M\u0026A, impairment, etc.), it is clearly material to investors assessing the company's clinical development progress and regulatory pathway for its lead candidate.","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":15958,"accession_number":"0001104659-26-082850","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, which the company characterizes as \"an important regulatory milestone\" on the path toward a future BLA. This is a material operational/regulatory milestone in the drug development process—it establishes the agreed framework for pediatric studies and is a prerequisite for BLA submission. While not a specific named event type (not earnings, M\u0026A, impairment, etc.), it is clearly material to investors assessing the company's clinical development progress and regulatory pathway for its lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:17:53.632150+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15958,"accession_number":"0001104659-26-082850","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Armata announced FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, which the company characterizes as \"an important regulatory milestone\" on the path toward a future BLA. This is a material operational/regulatory milestone in the drug development process—it establishes the agreed framework for pediatric studies and is a prerequisite for BLA submission. While not a specific named event type (not earnings, M\u0026A, impairment, etc.), it is clearly material to investors assessing the company's clinical development progress and regulatory pathway for its lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:17:53.632150+00:00","company_name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","filing_date":"2026-07-13"}]}